Jeena Sikho Q4 Results FY26: Revenue, PAT, Net Profit and Key Highlights

Jeena Sikho Q4 results for the quarter ended March 2026 show revenue of Rs 216 crore (+55% year on year) and net profit of Rs 45 crore (+67% year on year). Reported on a Standalone basis, these numbers reflect Jeena Sikho’s core Healthcare / Ayurveda performance through Q4 FY25-26. This article covers the full financial breakdown, margin analysis, and FY27 outlook to help investors make informed decisions about Jeena Sikho.

Click Here – Get Free Investment Predictions

Jeena Sikho Q4 FY26 Financial Highlights

The table below summarises key financial metrics comparing Q4 FY26 with Q4 FY25 on a Standalone basis.

Detailed Analysis of Jeena Sikho Q4 Results

Check the Univest Screener for live Jeena Sikho data

Revenue grew to Rs 216 crore in Q4 FY26 from Rs 139 crore in the year-ago quarter, a +55% change year on year. The Healthcare / Ayurveda segment drove the top line through this period, with demand conditions and pricing realisations shaping the quarterly revenue outcome. Investors tracking Jeena Sikho Q4 results are watching whether this revenue run rate sustains into FY27.

Gross profit stood at Rs 62 crore at a margin of 28.7%, compared to Rs 38 crore and 27.3% in Q4 FY25. The gross margin movement reflects input cost dynamics and product mix across Jeena Sikho’s operations. Kunal Singla, Associate Director at Univest, notes that margin outcomes in the Healthcare / Ayurveda sector are sensitive to commodity cost cycles that played out through Q4 FY26.

Net profit rose to Rs 45 crore from Rs 27 crore in Q4 FY25. At a PAT margin of 20.8%, the earnings quality reflects how efficiently Jeena Sikho is converting revenue to bottom-line income. Kunal Singla highlights that the Jeena Sikho Q4 results set a key profitability baseline for assessing FY27 earnings potential.

Key Business Factors in Q4 FY26

Revenue Drivers and Volume Trends

The +55% revenue change to Rs 216 crore in Q4 FY26 reflects Jeena Sikho’s demand conditions and order execution in the Healthcare / Ayurveda space. Volume performance, customer mix, and realisation per unit each contributed to the quarterly top-line figure. Whether this revenue level is sustainable into FY27 remains a key question for investors tracking the stock.

Gross Margin and Cost Management

A gross margin of 28.7% in Q4 FY26 reflects Jeena Sikho’s cost management posture within the Healthcare / Ayurveda segment. Input cost trends, freight expenses, and production efficiencies shaped this outcome. Sustaining or improving gross margins into FY27 will depend on Jeena Sikho’s ability to control costs as revenue scales through the year.

Profitability and Earnings Quality

Net profit of Rs 45 crore at a 20.8% PAT margin reflects Jeena Sikho’s earnings conversion in Q4 FY26. Finance costs, tax provisions, and non-operating items all influence the final PAT figure. The repeatability of these earnings will be central to how the company is valued heading into FY27.

Dividend Details

Jeena Sikho has not announced any dividend for Q4 FY26 as per information available on May 30, 2026. Investors should track official BSE/NSE filings for any board-level decisions on dividends or capital return for the full financial year FY26.

FY27 Outlook

Jeena Sikho enters FY27 with a revenue base of Rs 216 crore and net profit of Rs 45 crore from the Jeena Sikho Q4 results. The Healthcare / Ayurveda sector’s FY27 trajectory depends on domestic demand, input cost stability, and any regulatory changes that affect the broader operating environment.

Kunal Singla suggests that investors tracking Jeena Sikho should monitor quarterly management guidance, order book updates, and margin improvement milestones closely through H1 FY27. The transition from Jeena Sikho Q4 results into a full-year FY27 delivery is a critical inflection point for long-term shareholders in the stock.

Jeena Sikho Stock Performance

Download the Univest Android App or Univest iOS App to track Jeena Sikho share price and get daily research updates.

Jeena Sikho shares are trading at Rs 580.55 as of May 30, 2026. The stock’s reaction to Jeena Sikho Q4 results reflects how the market is assessing the company’s performance relative to Healthcare / Ayurveda sector expectations. Live price data, technical analysis, and research coverage for Jeena Sikho are available on the Univest platform.

Key Risks for Jeena Sikho

Healthcare / Ayurveda Sector Headwinds

The Healthcare / Ayurveda industry faces risks from commodity price swings, regulatory shifts, and competitive pressure. Any deterioration in sector fundamentals could weigh on Jeena Sikho’s revenue and margin outlook beyond Q4 FY26 levels.

Macroeconomic and External Risks

Global growth concerns, FII outflows, and domestic inflation pressures pose risks to Jeena Sikho’s valuation multiples independent of operational performance. A weak demand environment or rising interest rates could compress near-term earnings.

Execution and Working Capital Risk

Sustaining Q4 FY26 revenue and profitability levels into FY27 requires consistent execution from Jeena Sikho’s management. Receivable elongation, working capital build-up, or unexpected capex commitments could pressure future quarterly cash flows and earnings quality.

Conclusion

Jeena Sikho Q4 results for Q4 FY26 show revenue of Rs 216 crore and net profit of Rs 45 crore, establishing a clear picture of the company’s financial position in the Healthcare / Ayurveda space. The +55% revenue change and +67% PAT movement provide a meaningful baseline for FY27 projections. Kunal Singla recommends that investors review these numbers alongside sector trends and management commentary before making any investment decisions related to Jeena Sikho.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.

Frequently Asked Questions on Jeena Sikho Q4 FY26 Results

When were the Jeena Sikho Q4 results announced?

Ans. The Q4 FY26 results for Jeena Sikho were declared on May 30, 2026, covering the quarter ended March 2026.

What was the revenue in Jeena Sikho Q4 results?

Ans. Jeena Sikho reported revenue of Rs 216 crore in Q4 FY26, compared to Rs 139 crore in Q4 FY25, a change of +55% year on year.

What was the net profit in Jeena Sikho Q4 results?

Ans. Jeena Sikho reported a net profit (PAT) of Rs 45 crore in Q4 FY26, compared to Rs 27 crore in Q4 FY25, a +67% change year on year.

What is the FY27 outlook after Jeena Sikho Q4 results?

Ans. Jeena Sikho enters FY27 with revenue of Rs 216 crore and PAT of Rs 45 crore as a baseline. The FY27 outlook depends on Healthcare / Ayurveda demand, cost management, and execution quality.

Did Jeena Sikho declare a dividend after Jeena Sikho Q4 results?

Ans. No dividend was declared for Q4 FY26 as per information available on May 30, 2026. Investors should check official exchange filings for any board announcements on capital returns.

How did Jeena Sikho shares react to Jeena Sikho Q4 results?

Ans. Jeena Sikho shares are trading at Rs 580.55 as of May 30, 2026. The stock movement post-results reflects market assessment of the quarterly earnings against Healthcare / Ayurveda sector expectations.

Should investors buy Jeena Sikho shares based on Jeena Sikho Q4 results?

Ans. Investment decisions should factor in the full Q4 FY26 financials for Jeena Sikho, FY27 growth outlook, current valuation, and personal risk profile. Always consult a SEBI-registered investment adviser before investing.

What risks should investors watch after Jeena Sikho Q4 results?

Ans. Key risks for Jeena Sikho include Healthcare / Ayurveda sector headwinds, macroeconomic uncertainty, input cost volatility, and working capital pressure. Investors should track quarterly updates and management commentary to assess the risk-reward profile for the stock in FY27.